Comparing Hodgkin and Non-Hodgkin Lymphoma Mortality Between Latin America and the United States From 2008 to 2019: The Need of Regional-Based Lymphoma Registries Blockage of PD-1 with drugs such as ...
In 2021, CISL initiated a phase 2 clinical trial investigating a new therapeutic combination using cemiplimab, an anti-PD1 immune checkpoint inhibitor, and isatuximab, a monoclonal antibody that ...
A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...
The spliceosome targeting payload, PH1, demonstrates the ability to induce both cancer cell cytotoxicity and activation of anti-tumor immunity through multiple mechanisms Treatment with a ...
Medical advances tend to unfold slowly over many years, fueled by successive clinical studies that build upon each other and together provide the evidence needed to change patient care. A key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results